Provided by Tiger Trade Technology Pte. Ltd.

HIGHTIDE-B

3.510
-0.160-4.36%
Volume:477.00K
Turnover:1.71M
Market Cap:2.35B
PE:-6.88
High:3.850
Open:3.850
Low:3.480
Close:3.670
52wk High:4.720
52wk Low:1.800
Shares:670.00M
HK Float Shares:670.00M
Volume Ratio:0.65
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.510
ROE:-105.14%
ROA:-24.24%
PB:12.05
PE(LYR):-6.88
PS:58.84

Loading ...

HIGHTIDE-B Unveils New Share Incentive Grants

Stock News
·
Sep 01

HighTide Therapeutics Reports 1H26 Loss of RMB167.27 Million amid Investment Write-Down; Core Drug HTD1801 Advances Toward Commercialisation

Bulletin Express
·
Aug 31

HighTide FY26 H1 Net Loss Widens 46.9% to RMB 167.27 Million

Reuters
·
Aug 31

Shareholder Zhang Xiaolei Boosts Stake in HIGHTIDE-B by 10 Million Shares at HK$3.50 Each

Stock News
·
Aug 14

HighTide Therapeutics Sets 31 Aug 2026 Board Meeting to Approve Interim Results

Bulletin Express
·
Aug 14

HighTide Therapeutics Schedules Board Meeting to Review Interim Results

Reuters
·
Aug 14

Shares Worth HK$287 Million Deposited With Broker for HIGHTIDE-B, With Shareholder Transferring Over 52.6 Million Shares

Stock News
·
Aug 10

HIGHTIDE-B Finalizes 98.71 Million Share Placement

Deep News
·
Aug 09

HIGHTIDE-B's Strong Comeback: Examining the Impact of Recent Discounted Share Placements

Stock News
·
Aug 08

HighTide Therapeutics completes HK$225.10 million share placement, expanding issued share capital by 14.73%

Bulletin Express
·
Aug 07

HIGHTIDE-B expands share base by 17.28%, raises HK$225.05 million via share placement at HK$2.28

Bulletin Express
·
Aug 07

HIGHTIDE-B Keeps Issued Shares Flat at 571.33 Million in July 2026; Public Float Requirement Met

Bulletin Express
·
Aug 03

HIGHTIDE-B Plans to Issue Up to 99 Million Placement Shares at a Discount of Approximately 12.31%

Stock News
·
Jul 31

HighTide Therapeutics - to Issue up to 99 Mln New Shares at Hk$2.28 Per Share

THOMSON REUTERS
·
Jul 31

HighTide Therapeutics Plans Hk$225.72 Million Share Placement at Hk$2.28 Each

Reuters
·
Jul 31

HighTide Therapeutics Highlights NEJM Evidence Phase III Success of HTD1801 and Opens Talks on China Out-Licensing

Bulletin Express
·
Jul 10

HIGHTIDE-B's HTD1801 Clinical Trial Receives Positive Editorial Review

Stock News
·
Jul 10

Hightide Says Phase III Htd1801 Diabetes Trial Results Published in NEJM Evidence

Reuters
·
Jul 10

HighTide Therapeutics, CEO Terminate Loan Contract on Bourse's Concerns

MT Newswires Live
·
Jul 02

Hightide Therapeutics - Co and Individual Terminate Loan Agreement with Immediate Effect

THOMSON REUTERS
·
Jul 02